The Trump administration has thrown its support behind Bayer as the company urges the U.S. Supreme Court to review thousands of lawsuits alleging its Roundup weedkiller causes cancer. In a filing submitted by U.S. Solicitor General D. John Sauer, the administration argued that federal pesticide regulations should override state-level claims, reinforcing Bayer’s position that its product labels comply with long-established federal standards.
Bayer is seeking to overturn a lower court ruling that upheld a $1.25 million verdict for Missouri plaintiff John Durnell, who linked his non-Hodgkin’s lymphoma diagnosis to long-term Roundup exposure. The company currently faces more than 67,000 similar lawsuits nationwide. Bayer maintains that extensive scientific research and decades of Environmental Protection Agency (EPA) reviews show glyphosate—the active ingredient in Roundup—is safe when used as directed.
According to Sauer, allowing state courts to require different warning labels would undermine the EPA’s authority and lead to inconsistent regulatory standards. The EPA has repeatedly found that glyphosate is “not likely to be carcinogenic to humans,” and has approved labels without cancer warnings. Pro-business groups, including the U.S. Chamber of Commerce, also back Bayer, warning that upholding the ruling could expand liability for companies that comply with federal law.
Attorneys for Durnell urged the Supreme Court to reject Bayer’s appeal, arguing that the plaintiff relied not only on product labels but also on the company’s marketing, which failed to warn consumers of potential health risks.
Roundup remains one of the most widely used herbicides in the United States. While Bayer paid approximately $10 billion in 2020 to settle earlier claims, new lawsuits continue to emerge. The company has experienced mixed outcomes in court, including a massive $2.1 billion Georgia verdict that was later settled. As litigation intensifies, Bayer has warned that it may pull Roundup from the U.S. market and has already replaced glyphosate in consumer formulations with alternative weedkillers.


Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal
U.S. Announces Additional $6 Million in Humanitarian Aid to Cuba Amid Oil Sanctions and Fuel Shortages
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TrumpRx.gov Highlights GLP-1 Drug Discounts but Offers Limited Savings for Most Americans
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Trump Says “Very Good Talks” Underway on Russia-Ukraine War as Peace Efforts Continue
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Supreme Court Signals Doubts Over Trump’s Bid to Fire Fed Governor Lisa Cook
FDA Approves Mitapivat for Anemia in Thalassemia Patients
U.S. Lawmakers to Review Unredacted Jeffrey Epstein DOJ Files Starting Monday 



